Regulatory reviews for this indication are ongoing in China and Japan. Fabhalta received its first FDA approval in December 2023 for the treatment of adults with paroxysmal nocturnal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback